Kollef MH, Nováček M, Kivistik U, et al. - The efficacy and safety of the combination antibacterial drug ceftolozane–tazobactam vs meropenem for treatment of Gram-negative nosocomial pneumonia were determined via performing a randomized, controlled, double-blind, non-inferiority trial at 263 hospitals in 34 countries. From Jan 16, 2015, to April 27, 2018, a random assignment of 726 patients was done; 362 patients comprised the ceftolozane–tazobactam group and 364 comprised the meropenem group. Overall, ventilator-associated pneumonia was evident in 519 (71%) patients, Acute Physiology and Chronic Health Evaluation II scores of at least 20 were noted in 239 (33%), and there were 668 (92%) who were in the intensive care unit. The analysis suggests noninferiority of ceftolozane–tazobactam to meropenem in terms of both 28-day all-cause mortality and clinical cure at the test of cure. Outcomes support the efficacy and safety of providing high-dose ceftolozane–tazobactam for treating Gram-negative nosocomial pneumonia in mechanically ventilated patients, a high-risk, critically ill population.